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The impact of psoriasis on quality of life has been studied in select patient populations. Population-based data
detailing the distribution of extent of disease, associated problems in everyday life, and treatment satisfaction for
the US population have been lacking. Our population-based survey indicates that approximately 4.5 million adults
have been diagnosed as having psoriasis. Most (59%) have little or no involvement, but 650,000 adults have at least
three palms of body surface involved and more than 1,000,000 indicate substantial dissatisfaction with their
treatment. Only 5% of patients (56,000) who report severe dissatisfaction with current therapy have extensive
disease (10 palms). Many individuals with little psoriasis at the time of interview considered the disease to be a
large problem in everyday life.
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Psoriasis is a chronic skin disease most often manifested
as red scaling plaques. Although estimates of psoriasis
prevalence vary, it is common in many populations. The
body surface area affected and the degree to which
psoriasis is a problem varies considerably among patients
and over time. Select groups of patients commonly report
dissatisfaction with available therapy (Krueger et al, 2001).
Population-based estimates of the prevalence of psoriasis,
the distribution of area involved, problems in everyday life,
and treatment satisfaction among those affected in the
United States are lacking.
After years of receiving scant attention, psoriasis has
become a prominent focus of new drug development,
particularly of biologic therapies that target the immune
system (Griffiths, 2002). With the development of new thera-
peutic options for psoriasis, better information on disease
prevalence and problem in everyday life is particularly useful.
Results
Prevalence and demographic characteristics Of the
27,220 completed interviews, 601 (2.2%) respondents
reported having been diagnosed by a physician with
psoriasis (Table I). We estimate that there are 4.55 million
persons (95% CI, 4.15–4.95) age 18 or older in the
contiguous United States in 2001 who had been diagnosed
as having psoriasis. Patients reporting psoriasis were
more likely to be women (OR, 1.37; 95% CI, 1.14–1.64).
Prevalence increases significantly with age to age 35 (1.4%,
age 18–25; 2.1% age 25–35; po0.01) but did not vary
significantly after age 35 (range, 2.4%–2.5%) (Table I).
Compared to white respondents, black respondents were
significantly less likely to report having been diagnosed by a
physician with psoriasis (OR, 0.54; 95% CI, 0.34–0.85). The
distribution of income and education did not differ sig-
nificantly between persons reporting psoriasis and others
(data not shown).
Extent, problem, and treatment satisfaction Table II
provides the distribution of reported problem caused by
the disease in everyday life, extent, and treatment satisfac-
tion among persons reporting psoriasis. Approximately one-
half million persons find their psoriasis a large problem and
1 million are dissatisfied with its therapy. Forty percent of
the estimated half million persons who indicate psoriasis is
a substantial problem had at least three palms of psoriasis
at the time of their interview (Fig 1). Patients who classified
their psoriasis as a large problem were three times more
likely to be dissatisfied with treatment than other patients
(OR, 3.34; 95% CI, 1.86–6.00). Among those reporting
limited current skin involvement (one or two palms covered),
approximately 800,000 persons indicate substantial dis-
satisfaction with therapy (Fig 1).
More than 300,000 patients with at least 3 or more palms
of coverage were dissatisfied with therapy and/or found
the disease to be a large problem. Persons with at least
10 palms of coverage were much more likely to report
that psoriasis was a large problem (OR, 14.50; 95% CI,
5.00–42.04) and more likely to indicate dissatisfaction
with therapy (OR, 3.14; 95% CI, 1.20–8.23) than those with
little psoriasis at the time of interview.Abbreviation: CI, confidence interval(s)
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Consistency between surveys One contract survey orga-
nization interviewed 16,050 (59.0%) of the 27,220 respon-
dents and the other the remaining persons. The estimated
prevalence of psoriasis was comparable for data derived
from both organizations (2.3% (95% CI, 2.0–2.5) and
2.1% (95% CI, 1.8–2.4), respectively). Also, the estimated
proportion of persons with psoriasis who were women was
comparable for the data from both organizations (60 and
58%, respectively). Data from both survey organizations
also estimated comparable proportions of affected persons
with substantial psoriasis (three or more palms) (15 and
13%, respectively) and of those who were not satisfied with
treatment (46 and 52%, respectively).
Discussion
Prior studies provide limited population-based assessment
of psoriasis prevalence, morbidity, and satisfaction with
treatment. Our study confirms that psoriasis is common,
affecting more than 2% of US adults (Koo, 1996). As a result
of the natural history of the disease and therapy, most
patients have limited involvement at any time. Nevertheless,
psoriasis is not simply a cosmetic problem. Even patients
with limited involvement often find their disease a large
problem in everyday life. Only 120,000 persons (0.06% of
the US population) report more than 10 palms of coverage,
but one-half million Americans find this disease to be a large
problem. Nearly 60% of persons reporting their disease to
be a large problem and nearly 80% of persons who were
very dissatisfied with their treatment had less than 10 palms
of coverage.
In contrast to approximately equal prevalence calculated
by some other studies, our large population-based study
determined that women more frequently reported a physi-
cian’s diagnosis of psoriasis than some other studies’
findings (Farber and Nall, 1974; Koo, 1996; Nevitt and
Hutchinson, 1996). This difference in sex was not ac-
counted for by age or extent of disease (data not shown).
Possible explanations include recall bias and diagnostic
bias, which may reflect women being more likely to seek
medical care. For example, women account for nearly 60%
of ambulatory visits to dermatologists (Stern and Nelson,
1993).
Strengths and limitations Random-digit dialing is widely
used and a well-accepted method for population-based
health research including cross-sectional surveys such as
ours. Nevertheless, it has several potential biases such as
noncoverage of households without telephone and poten-
tially low and often unknown response rates (Brogan et al,
2001). To account for differences in the demographic
characteristics of respondents and the general US popula-
tion representation of the survey participants’ observations
were weighted accordingly to reflect the differences in the
distribution of these characteristics among respondents
Table I. Distribution of demographic characteristics of all survey respondents and those diagnosed with psoriasis and estimated
number of persons and psoriasis prevalence in continental United States by those demographic characteristics
Variables
No. of
survey
respondents
(%)
Estimates of
persons in
US
populationa
in millions
(95% CI)
No. of
persons with
psoriasisb
(%)
Estimates (in
thousands) of persons
with psoriasis in US
populationa (95% CI)
Prevalence (%) of
psoriasis in
continental United
States (95% CI)
Total 27,220 203.9 601 4550 (4150–4951) 2.2 (2.0–2.4)
Sex
Male 13,146 (48) 98.6 (97.2–100.0) 244 (41) 1844 (1593–2095) 1.9 (1.6–2.1)
Female 14,074 (52) 106.4 (105.0–108.0) 357 (59) 2705 (2393–3016) 2.5 (2.3–2.8)
Age (years)
18–24 2772 (10) 24.4 (23.4–25.4) 32 (5) 332 (192–472) 1.4 (0.8–1.9)
25–34 4647 (17) 38.2 (37.0–39.3) 92 (15) 781 (602–960) 2.1 (1.5–2.5)
35–44 5554 (20) 45.3 (44.2–46.5) 128 (21) 1093 (889–1298) 2.4 (2.0–2.9)
45–54 5482 (20) 36.6 (35.6–37.5) 132 (22) 888 (721–1054) 2.4 (2.0–2.9)
55–64 3552 (13) 23.9 (23.1–24.7) 95 (16) 623 (494–571) 2.6 (2.1–3.1)
465 4669 (17) 32.6 (31.7–33.5) 120 (20) 816 (665–966) 2.5 (2.1–3.0)
Ethnicity
White 21,921 (81) 165.8 (164.0–167.0) 541 (90) 4090 (3717–4464) 2.5 (2.2–2.7)
Black 2443 (9) 21.2 (20.3–22.1) 27 (5) 271 (151–392) 1.3 (0.7–1.8)
Other 2856 (10) 18.0 (17.2–18.7) 33 (5) 187 (119–254) 1.0 (0.7–1.4)
aAge 18 or older.
bPersons who reported having been diagnosed by a physician with psoriasis. Up to 4% of data missing (question refused or not answered). Therefore,
sum of all strata may be less than 601 and less than 4,550,000, respectively.
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and the general population (Stata Corporation, 2003). Some
studies suggest that this sampling procedure overrepre-
sents persons with higher income and better education
(Olsen et al, 1992; Mickey et al, 1994). Because persons
with a higher socioeconomic status may be more likely to
seek medical care for their psoriasis, an ascertainment
bias leading to a higher estimate of prevalence is possible.
Nevertheless, the distribution of income and education
among persons diagnosed with psoriasis and other survey
participants are comparable. Therefore, the extent of this
bias is likely to be small. The consistency of the results
between the two independent survey organizations sug-
gests that sampling bias is small or absent and that
combining the data collected by the two organizations is
appropriate. Because the survey was introduced as a
‘‘general health survey’’ and the first questions did not ask
about psoriasis, substantial response bias is unlikely. Recall
bias may have affected our results.
There are a number of other limitations of this study. The
validity of self-reported psoriasis has not been studied,
but in other common chronic diseases it appears to
be reasonably accurate (Martin et al, 2000). When com-
pared to physician evaluation, a self-administered psoriasis
severity questionnaire showed good agreement between
physicians and patients but a different measure of involve-
ment, which included extent as one element, was used
(Feldman et al, 1996). Not surprisingly, using our self-
reported extent of disease, our population-based sample
indicates a smaller proportion of patients with extensive
psoriasis than reported previously in clinic-based studies
(Fleischer et al, 1996). Our questions on treatment satisfac-
tion and disease burden, or problem of the disease in
everyday life, are necessarily subjective. Individual patients’
Figure 1
Distribution (and number in millions) of extent of burden and
treatment satisfaction among patients with a diagnosis of
psoriasis by extent of body surface involved at time of interview.
Table II. Distribution of disease characteristics of survey respondents diagnosed with psoriasis and estimated number of persons
and psoriasis prevalence in continental United States with psoriasis by those disease characteristics
Variable
No. of persons with
psoriasis from the
surveya (%)
Estimates (in
thousands) of number
of persons with
psoriasis in US
populationb (95% CI)
Prevalence (%) of
psoriasis in USb (95% CI)
Total 601 4550 (4150–4951) 2.2 (2.0–2.4)
Current extent of disease
No or little 333 (59) 2638 (2333–2954) 1.3 (1.2–1.5)
1–2 palms 153 (24) 1146 (951–1341) 0.6 (0.5–0.7)
3–10 palms 73 (11) 506 (380–631) 0.3 (0.2–0.3)
410 palms 21 (3) 120 (66–175) 0.01 (0.00–0.02)
General problem in everyday life (1–10 scale)
1–3 (no or little) 352 (60) 2684 (2429–2939) 1.3 (1.2–1.5)
4–7 (a problem) 163 (28) 1278 (1070–1486) 0.6 (0.5–0.7)
8–10 (a large
problem)
73 (12) 489 (374–605) 0.2 (0.1–0.3)
Treatment satisfaction (1–10 scale)
1–3 (dissatisfied) 140 (25) 1025 (855–1195) 0.5 (0.4–0.6)
4–7 (somewhat
satisfied)
153 (27) 1182 (983–1380) 0.6 (0.5–0.7)
8–10 (satisfied) 272 (48) 2055 (1821–2290) 1.0 (0.9–1.1)
aPersons who reported having been diagnosed by a physician with psoriasis. Up to 4% of data missing (question refused or not answered). Therefore,
sum of all strata may be less than 601 and less than 4,550,000, respectively.
bAge 18 or older.
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extent of disease will vary over time and perhaps
seasonally, but our estimate of the distribution of extent in
the population is likely to be robust for the fall season when
interviews were done.
Implications Our survey documents that psoriasis is not
only common but also has a substantial negative impact on
everyday life for a large number of persons. In addition
to new therapies for patients with moderate to severe
psoriasis, innovations in psoriasis therapy are needed for
the nearly 1 million US residents with less extensive but
often troubling disease (Finlay and Coles, 1995; Krueger
et al, 2001).
Materials and Methods
Survey procedures In late 2001, the National Psoriasis Founda-
tion commissioned two contract survey organizations to contact a
general population sample of persons age 18 or older representa-
tive of residents of the contiguous 48 United States. Both
organizations surveyed independently. They used the same
sampling procedure and questionnaire. Households to be con-
tacted were selected by random digit dialing and were called up to
three times before being replaced by a next randomly selected
telephone number in the contiguous 48 United States. Each
response was weighted according to standard methods (Stata
Corporation, 2003). One survey organization developed weights
based on the distribution of respondents compared to that of the
US population stratified by sex, age, ethnicity, and region and the
other used the same methods and stratification variables, except
they excluded region. In our primary analysis, data collected by
both organizations were analyzed together. To assess consistency
between the two survey organizations, we compared estimates of
selected endpoints based on the two survey groups’ data.
Study variables We asked all participants questions concerning
sociodemographic characteristics and whether they had ever been
diagnosed by a physician as having psoriasis. We asked patients
who indicated a diagnosis of psoriasis to estimate extent of
involvement, the extent to which psoriasis had been a problem in
everyday life, satisfaction with treatment, and the specialties of
physicians seen for this condition. Respondents were asked to
estimate the extent of their psoriasis in one of four categories ‘‘little
or none’’ or according to number of palms to cover their psoriasis
(1–2, 3–10, or410 palms). Using 10-point Likert scale (1¼ not,
10¼ very great), we asked patients to assess both how much of a
problem their psoriasis was in everyday life and their satisfaction
with treatment. We classified the responses in the 3 (of 10) highest
ratings as a large problem or dissatisfied with treatment, the 4
middle responses (4–7) as a problem or somewhat satisfied with
treatment and the 3 lowest ratings as no or little problem
or satisfied with treatment. We received a waiver not requiring
written consent from the Western IRB. Participation was voluntary
and the study fully conformed to the guidelines of the Declaration
of Helsinki.
Statistical methods The sampling design of the study yielded
sampling weights (probability weights) for each observation, which
permit calculation of point estimates. We used Stata (Version 7,
Stata Corporation, College Station, TX) procedures for survey data
to estimate the number of persons and 95% confidence intervals
(95% CI) age 18 or older with psoriasis in the United States in 2001
as well as demographic and disease characteristics of those
affected. We used logistic regression models for survey data to
determine patients’ attributes associated with higher odds (and
95% CI) of reporting psoriasis as a large problem and/or being
dissatisfied with psoriasis treatment. The multivariate estimates
were adjusted for all other variables significantly associated with
that endpoint in the univariate analyses.
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